Replies to post #87939 on Biotech Values

[mcbio]

Re: INCY (vs. RIGL)

90 million upfront for a drug that doesn't even have phase II data yet. Color me shocked as I did not think they would get anything near this sum, especially given the limited data at hand.

Friedman's performance this year has been quite impressive.

Good news for INCY and a continued bearish sign for RIGL's R788 as it was passed over again.

[microcapfun]

>>90 million upfront for a drug that doesn't even have phase II data yet. Color me shocked as I did not think they would get anything near this sum, especially given the limited data at hand.<<

The RA data was convincing enough for Incyte's first JAK inhibitor, INCB18424, and everybody knows the company split one drug into two for marketing purposes. Plus I assume Lilly saw some solid interim data from the P2 trial with the 2nd JAK inhibitor.

I posted previously how the MPD/oncology deal with Novartis allowed Incyte to keep significant rights.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=43917275
They have already begun to monetize them. A slick move.


>>Friedman's performance this year has been quite impressive.<<

Yeah. And INCY has been good to me this year ...

micro